share_log

T2 Biosystems | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Nathan D. Hukill(69.5%),CR Group L.P.(69.5%), etc.

T2 Biosystems | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Nathan D. Hukill(69.5%),CR Group L.P.(69.5%), etc.

T2 Biosystems | SC 13D/A：超過5%持股股東披露文件(修正)-Nathan D. Hukill(69.5%),CR Group L.P.(69.5%)等
美股sec公告 ·  05/14 07:24
牛牛AI助理已提取核心訊息
On May 9, 2024, T2 Biosystems, Inc., a medical diagnostic company, experienced a significant change in its ownership structure as detailed in an amended Schedule 13D filing with the U.S. Securities and Exchange Commission. The filing indicates that a group led by Nathan D. Hukill, including entities such as CR Group L.P. and various CRG Partners funds, has acquired a substantial portion of the company's common stock. The shares were obtained in exchange for the cancellation of outstanding loans previously extended to T2 Biosystems under a Term Loan Agreement dating back to December 30, 2016. As a result of these transactions, the group collectively holds approximately 69.5% of the issued and outstanding shares of T2 Biosystems' common stock. This percentage includes shares acquired through the conversion...Show More
On May 9, 2024, T2 Biosystems, Inc., a medical diagnostic company, experienced a significant change in its ownership structure as detailed in an amended Schedule 13D filing with the U.S. Securities and Exchange Commission. The filing indicates that a group led by Nathan D. Hukill, including entities such as CR Group L.P. and various CRG Partners funds, has acquired a substantial portion of the company's common stock. The shares were obtained in exchange for the cancellation of outstanding loans previously extended to T2 Biosystems under a Term Loan Agreement dating back to December 30, 2016. As a result of these transactions, the group collectively holds approximately 69.5% of the issued and outstanding shares of T2 Biosystems' common stock. This percentage includes shares acquired through the conversion of Series A and Series B Convertible Preferred Stock on May 9, 2024. The filing also notes that no other transactions in the common stock have been made by the reporting persons in the last 60 days, and no other person is known to have the right to receive dividends or proceeds from the sale of the shares owned by the reporting group.
2024年5月9日，醫療診斷公司T2 Biosystems, Inc. 的所有權結構發生了重大變化，詳情見向美國證券交易委員會提交的經修訂的附表13D。文件顯示，由內森·哈基爾領導的集團，包括CR集團有限責任公司和各種CRG Partners基金等實體，已經收購了該公司很大一部分普通股。獲得這些股份是爲了換取取消先前根據可追溯到2016年12月30日的定期貸款協議向T2 Biosystems提供給T2 Biosystems的未償貸款。由於這些交易，該集團共持有T2 Biosystems普通股已發行和流通股的約69.5％。該百分比包括2024年5月9日通過轉換A系列和B系列可轉換優先股獲得的股份。該文件還指出，在過去的60天中，申報人沒有進行任何其他普通股交易，據知沒有其他人有權獲得分紅或出售申報集團擁有的股票的收益。
2024年5月9日，醫療診斷公司T2 Biosystems, Inc. 的所有權結構發生了重大變化，詳情見向美國證券交易委員會提交的經修訂的附表13D。文件顯示，由內森·哈基爾領導的集團，包括CR集團有限責任公司和各種CRG Partners基金等實體，已經收購了該公司很大一部分普通股。獲得這些股份是爲了換取取消先前根據可追溯到2016年12月30日的定期貸款協議向T2 Biosystems提供給T2 Biosystems的未償貸款。由於這些交易，該集團共持有T2 Biosystems普通股已發行和流通股的約69.5％。該百分比包括2024年5月9日通過轉換A系列和B系列可轉換優先股獲得的股份。該文件還指出，在過去的60天中，申報人沒有進行任何其他普通股交易，據知沒有其他人有權獲得分紅或出售申報集團擁有的股票的收益。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。